Public procurement notice: Contract Notice
Published: 2016-11-26
Buyer: The Common Services Agency (more commonly known as NHS National Services Scotland) (‘the Authority’)
Country: UK
Region: SCOTLAND
Contract type: Supplies
Procedure: Open procedure
CPV classification: 33600000: Pharmaceutical products | 33631100 | 33651400
Estimated value: 2250000 GBP
Submission deadline: 2017-01-10
Award criteria: The most economic tender

Technical requirements: The supply of a Valganciclovir tablets and oral solution and Caspofungin 50mg and 70mg Powder for Solution for Infusion vials to Health Boards across NHS Scotland.
All entities constituted pursuant to the National Health Service (Scotland) Act 1978, and any Integrated Joint Boards established pursuant to the new Public Bodies (Joint Working) Scotland Act 2014.
Each product line will be treated as an individual Lot and be awarded on a line by line basis as a single supplier framework.
The Authority is entitled at its sole discretion to extend the Framework Agreement by up to a further two (2) periods of up to twelve (12) months each by giving a minimum of three (3) months written notice of such extension.
Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by approved by the MHRA for all tendered Medicines at the date of submission of the tender.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA Best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (‘NPSA’) Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants and any sub-contractor(s) must possess a UKAS (or equivalent) accredited independent third party certificate of compliance with BS EN ISO 14001 (or equivalent) or a valid EMAS (or equivalent) certificate.
(a) Confirmation of existence of a valid and current UK Marketing Authorisation or EMA Marketing Authorisation that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Technical and Professional ability: Quality Control.
(b) Confirmation of the existence of valid certification of BS EN ISO 9001 or equivalent. Confirmation of such certification should be included in the Qualification Envelope of the ITT under the Quality Assurance Schemes.
(c) Confirmation that samples for tendered Goods will be supplied upon request to ensure compliance with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency (‘NPSA’) Guidelines on Packaging and Labelling on pack design. Confirmation of sample provision should be provided in the Qualification Envelope of the ITT under Technical and Professional ability: Products.
(d) Confirmation of the existence of certificates drawn up by independent bodies attesting the compliance with the required environmental management systems or standards should be included in the Qualification Envelope of the ITT under Environmental Management Standards.
The estimated value referred to in Sections II.I.5 and II.2.6 covers the initial twelve (12) months duration of the Framework Agreement and the available twenty-four (24) months extension options.
The buyer is using PCS-Tender to conduct this ITT exercise. The Project code is 7248. For more information see: http://www.publiccontractsscotland.gov.uk/info/InfoCentre.aspx?ID=2343

Eligibility requirements: Economic operators may be excluded from this competition if they are in breach of any of the situation referred to in regulation 58 of the Public Contracts (Scotland) Regulations 2015.

Award value: 2250000